Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125305061 | 12530506 | 1 | I | 20160628 | 20160706 | 20160706 | EXP | ZA-GLAXOSMITHKLINE-ZA2016GSK095757 | GLAXOSMITHKLINE | 61.00 | YR | F | Y | 0.00000 | 20160706 | OT | ZA | ZA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125305061 | 12530506 | 1 | PS | LAMIVUDINE. | LAMIVUDINE | 1 | U | 21003 | |||||||||||
| 125305061 | 12530506 | 2 | SS | STAVUDINE. | STAVUDINE | 1 | U | 0 | |||||||||||
| 125305061 | 12530506 | 3 | SS | EFAVIRENZ | EFAVIRENZ | 1 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125305061 | 12530506 | 1 | HIV infection |
| 125305061 | 12530506 | 2 | HIV infection |
| 125305061 | 12530506 | 3 | HIV infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125305061 | 12530506 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125305061 | 12530506 | Drug resistance | |
| 125305061 | 12530506 | Hepatitis B | |
| 125305061 | 12530506 | Treatment failure | |
| 125305061 | 12530506 | Virologic failure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |